Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Q4 2021 Arrowhead Pharmaceuticals Inc Earnings Call Transcript

Nov 22, 2021 / 09:30PM GMT
Release Date Price: €62.98 (+1.32%)
Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. (Operator Instructions)

I will now hand the conference call over to Vince Anzalone, Vice President of Investor Relations for Arrowhead. Please go ahead.

Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its 2022 -- 2021 fiscal year ended September 30, 2021.

With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our pipeline; and Kenneth Myszkowski, our Chief Financial Officer, who will give a review of the financials. In addition, Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine, will be available during the Q&A session of today's call.

Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot